What is it about?
Cancer is not a uniform population of identical cells. Tumours contain different cancer cell clones that compete for space and resources, and some may have characteristics that give them a survival advantage. This Clinical Brief considers cancer from an evolutionary perspective, focusing on how chemotherapy acts as a selective pressure that can eliminate sensitive cells while allowing resistant clones to survive and expand.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Treatment resistance is a major challenge in cancer. When treatment removes susceptible tumour cells, resistant clones may gain access to space and resources that were previously occupied by their competitors. These surviving cells can then proliferate and contribute to disease relapse. Viewing treatment resistance through an evolutionary lens highlights why understanding tumour heterogeneity and the selective pressures acting within tumours is important for developing better treatment strategies
Perspectives
An evolutionary understanding of cancer may help identify alternative ways to manage therapeutic resistance. Rather than relying exclusively on strategies designed to eliminate tumour cells, approaches could potentially manipulate competition between clones, alter the tumour microenvironment or exploit trade-offs associated with resistance. Advances in genetic profiling, single-cell analysis and computational modelling may also improve our ability to understand how tumour populations change during treatment and identify strategies for controlling their evolution.
Dr Catherine Worsley
University of Pretoria
Read the Original
This page is a summary of: Clone wars: the evolution of therapeutic resistance in cancer, Evolution Medicine and Public Health, January 2016, Oxford University Press (OUP),
DOI: 10.1093/emph/eow015.
You can read the full text:
Contributors
The following have contributed to this page
